Orchard Therapeutics to present clinical data for OTL-101 & OTL-102
Category: #health  By Saipriya Iyer  Date: 2019-02-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Orchard Therapeutics to present clinical data for OTL-101 & OTL-102

Biopharma major Orchard Therapeutics has reportedly made it to the front page for having announced details of oral and poster presentations for new clinical data. As per sources familiar with the knowledge of the matter, the prominent commercial-stage biopharmaceutical firm’s new clinical data for OTL-101 and OTL-102 will be presented at the TCT (Transplantation and Cellular Therapy) Meetings of the CIBMTR (Center for International Blood and Marrow Transplant Research) and the ASBMT (American Society of Blood and Marrow Transplantation).

The presentations at both the ASBMT and the CIBMTR will be held between February 20 to February 24, 2019, at Houston, Texas.

According to an official press release by Orchard Therapeutics, Donald B. Kohn, M.D., Professor, Microbiology, Immunology & Molecular Genetics, University of California, LA, will be presenting clinical data from a current registrational clinical trial of OTL-101. The latter incidentally, is used for the treatment of ADA-SCID (adenosine deaminase severe combined immunodeficiency).

Reliable sources with the knowledge of the matter affirm that Dr. Kohn will also be responsible for presenting a detailed clinical proof-of-concept data for OTL-102, that is used for treating X-CGD (X-linked chronic granulomatous disease) – highlighted at the time of the Presidential Symposium, at the 2018 American Society of Hematology Annual Meeting and Exposition held in December.

As per credible reports, the oral presentation for OTL-101 and OTL-102 will focus on gene therapy for ADA-SCID and Lentiviral Gene Therapy for X-CGD (X-linked Chronic Granulomatous Disease) to be held at the George R. Brown Convention Center and Hilton Americas Houston respectively. The poster presentation for OTL-101, on the other hand, will revolve around autologous Ex Vivo Lentiviral Gene Therapy for treating ADA-SCID (Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency), also to be held at the George R. Brown Convention Center.

A completely integrated, commercial-stage biopharma magnate, Orchard Therapeutics is committed to transforming the lives of patients afflicted with life-threatening rare diseases through via highly innovative gene therapies.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Raspberry Pi opens its inaugural brick-and-mortar retail store
Raspberry Pi opens its inaugural brick-and-mortar retail store
By Saipriya Iyer

Raspberry Pi is one among the many online retailers that is expanding offline to gain more customers.

Raspberry Pi has reportedly opened its very first brick-and-mo...

Rutgers & Horizon plan to commercialize CRISPR base editing technology
Rutgers & Horizon plan to commercialize CRISPR base editing technology
By Saipriya Iyer

Horizon has also agreed to fund further research in base editing at the Rutgers University.

Horizon Discovery Group plc, one of the globally reputed gene editing in...

Otsuka-Click alliance on digital therapeutics to help MDD patients
Otsuka-Click alliance on digital therapeutics to help MDD patients
By Saipriya Iyer

Otsuka America, Inc., and Click Therapeutics, Inc., have reportedly announced that they have signed an agreement to develop and commercialize a digital therapeutic for the treatment of MDD. The partnership aims to prov...